The objective of this proposal is to advance medication development for alcohol use disorder
by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator,
as a potential treatment. This study has important clinical implications, as the available
treatments for alcohol use disorder are only modestly effective and testing novel medications
is a high research priority.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland, Baltimore
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)